About us

 

History

 
A world leader in the field of in vitro diagnostics for 45 years, bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

The Mérieux have a family tradition and a century-long commitment to the fight against infectious diseases. Marcel Mérieux, who worked with Louis Pasteur and founded the Mérieux Institute, Dr. Charles Mérieux, Alain Mérieux and Dr. Christophe Mérieux have devoted their lives to biology with a goal of improving health worldwide. By creating bioMérieux in 1963, Alain Mérieux, its president, has carried on this family tradition.
 
Today, bioMérieux has more than 6,000 employees. Headquartered in France, the company is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2008, revenues reached €1.111 billion with 84% of sales outside of France. bioMérieux is listed on NYSE Euronext Paris.
 

Company Milestones

1897


 
Marcel Mérieux creates the Institut Mérieux, which developed a large range of vaccines and biological
products, including reagents. Alain Mérieux was president of the Institut for 25 years, until 1994
1963 
Creation of BD Mérieux equally owned by Institut Mérieux and Becton Dickinson
1974     
   
Alain Mérieux takes majority control of the company: BD Mérieux becomes bioMérieux
1986         API Systems (France) acquisition
1988        Vitek acquisition from McDonnel Douglas (U.S.)
2001    
    
Organon Teknika Diagnostic acquisition from Akzo Nobel (Netherlands)
2003 40th anniversary
2004 Listing of bioMérieux on the stock exchange
2006


 
Inauguration of the Christophe Mérieux Center, dedicated to molecular biology and microsystems research (Grenoble, France) 
Bacterial Barcodes (U.S.) acquisition - DiversiLab™
2007
 
Biomedics (Spain) acquisition
BTF (Australia) acquisition
2008



 
Joint venture with Sysmex (Japan)
Joint venture with Shanghai Kehua Bio-engineering (China)
AB BIODISK (Sweden) acquisition
AviaraDx (U.S.) acquisition - renamed bioTheranostics, Inc.
PML Microbiologicals (U.S.) acquisition

  
More information on bioMérieux can be found at: www.biomerieux.com